Why join Freenome?
Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. To do this, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to find cancer in its earliest, most-treatable stages.
Cancer is relentless. This is why Freenome is building the clinical, economic, and operational evidence to drive cancer screening and save lives. Our first screening test is for colorectal cancer (CRC) and advanced adenomas, and it’s just the beginning.
Founded in 2014, Freenome has ~400 employees and continues to grow to match the scope of our ambitions to provide access to better screening and earlier cancer detection.
At Freenome, we aim to impact patients by empowering everyone to prevent, detect, and treat their disease. This, together with our high-performing culture of respect and cross-collaboration, is what motivates us to make every day count.
Become a Freenomer
Do you have what it takes to be a Freenomer? A “Freenomer” is a determined, mission-driven, results-oriented employee fueled by the opportunity to change the landscape of cancer and make a positive impact on patients’ lives. Freenomers bring their diverse experience, expertise, and personal perspective to solve problems and push to achieve what’s possible, one breakthrough at a time.
About this opportunity:
At Freenome, we are seeking an Associate Development Scientist to help grow our Genomics Assay Development team. At Freenome, you will help develop the assay technologies used to analyze patient samples and contribute to our mission of early cancer detection. The ideal candidate will work to develop assay technologies for our multiomic platform manually and on robotic platforms. You will develop, characterize, verify, and validate clinical-grade assays to measure complex, blood-based analytes (e.g., whole-genome sequencing of cfDNA). You will work cross-functionally with Research & Development teams, automation and process engineering, computational science, and clinical operations to develop and transfer NGS-based assays in a regulated, high-throughput environment. You are passionate about developing life saving diagnostics using NGS technologies, and you will have a significant impact on the continued growth of an organization dedicated to changing the entire landscape of cancer.
This role reports to the Manager of Genomics Late Stage Development. This role will be an onsite role based in our Brisbane, California headquarters.
What you’ll do:
Must haves:
Nice to haves:
Benefits and additional information:
The US target range of our base salary rate for new hires is $104,975 - $159,500. You will also be eligible to receive pre-IPO equity, cash bonuses, and a full range of medical, financial, and other benefits depending on the position offered. Please note that individual total compensation for this position will be determined at the Company’s sole discretion and may vary based on several factors, including but not limited to, location, skill level, years and depth of relevant experience, and education. We invite you to check out our career page @ freenome.com/job-openings/ for additional company information.
Freenome is proud to be an equal-opportunity employer, and we value diversity. Freenome does not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.
Applicants have rights under Federal Employment Laws.
#LI-Onsite